Anemia due to chronic disorder
diseaseOn this page
Also known as anaemia due to Chronic Disorderanaemia of chronic diseaseanaemia of chronic disorderanaemia of chronic illnessanaemia of chronic inflammationanaemia of systemic diseaseanemia of chronic diseaseanemia of chronic disorderanemia of chronic illnessanemia of chronic inflammationanemia of systemic diseaseSecondary anaemiaSecondary anemia
Summary
Anemia due to chronic disorder (MONDO:0020725) is a disease and 9 clinical trials. Top therapeutic interventions include calcitriol, epoetin alfa, and iron sucrose. A subtype of anemia — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Clinical trials: 9
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | anemia due to chronic disorder |
| Mondo ID | MONDO:0020725 |
| NCIT | C35659 |
| SNOMED CT | 234347009 |
| UMLS | C0002873 |
| MedGen | 507442 |
| Is cancer (heuristic) | no |
Also known as: anaemia due to Chronic Disorder · anaemia of chronic disease · anaemia of chronic disorder · anaemia of chronic illness · anaemia of chronic inflammation · anaemia of systemic disease · anemia due to chronic disorder · anemia of chronic disease · anemia of chronic disorder · anemia of chronic illness · anemia of chronic inflammation · anemia of systemic disease · Secondary anaemia · Secondary anemia
Disease family
This is a subtype of anemia. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by body system or component › hematologic disorder › anemia › anemia due to chronic disorder
Related subtypes (18): congenital anemia, neonatal anemia, microcytic anemia, hypochromic anemia, pancytopenia, deficiency anemia, pure red-cell aplasia, macrocytic anemia, normocytic anemia, sideroblastic anemia, aplastic anemia, hemoglobin C disease, hemoglobin E disease, beta-thalassemia and related diseases, hemoglobinopathy Toms River, hereditary methemoglobinemia, hemoglobin D disease, anemia due to enzyme disorder
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 9.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE2 | 3 |
| Not specified | 3 |
| PHASE3 | 1 |
| PHASE1 | 1 |
| EARLY_PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT01846689 | PHASE3 | UNKNOWN | An Open-label Trial to Determine Increased Red Blood Cell Production in Subjects With Anemia of Chronic Disease |
| NCT01691040 | PHASE2 | COMPLETED | Efficacy of NOX-H94 on Anemia of Chronic Disease in Patients With Cancer |
| NCT01873534 | PHASE2 | TERMINATED | A Phase 2A Trial of FMX-8 Treatment for Anemia in Patients With ESRD on Hemodialysis HD |
| NCT03528564 | PHASE2 | TERMINATED | Hemoglobin Optimization to Prevent Transfusion and Adverse Events in Perioperative Patients With Iron Restricted Anemia |
| NCT01522794 | PHASE1 | COMPLETED | Pharmacokinetics/Pharmacodynamics of NOX-H94 in the Human Endotoxemia Model |
| NCT01988116 | EARLY_PHASE1 | COMPLETED | Effects of Vitamin D Replacement on Hormones Regulating Iron Metabolism in Individuals With Chronic Kidney Disease |
| NCT03978260 | Not specified | COMPLETED | Preoperative Anaemia prevaLence In surgiCal patiEnts |
| NCT04071067 | Not specified | UNKNOWN | Anemia of Inflammation and Deficiency Anemia |
| NCT05217836 | Not specified | UNKNOWN | Iron Metabolism Disorders in Patients With Sepsis or Septic Shock. |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| CALCITRIOL | 4 | 1 |
| EPOETIN ALFA | 4 | 1 |
| IRON SUCROSE | 4 | 1 |
| LEXAPTEPID PEGOL | 2 | 2 |
Related Atlas pages
- Drugs: Calcitriol, Epoetin Alfa, Iron Sucrose